Chair: Iris Grossman, PhD, Chief Scientific Officer, Camp4 Therapeutics
11:50-12:00 Iris Grossman, PhD, Chief Scientific Officer, Camp4 Therapeutics: “Introduction”
12:00-12:20 Iris Grossman, PhD, Chief Scientific Officer, Camp4 Therapeutics: “Regulatory Landscape, from Cures Act to INFORMED, Recent Guidances and Future Perspective”
12:20-12:35 Erhan Bilal, PhD, IBM Research, Computational Biology Center: “Sensor-based Assessment of Parkinson’s Disease”
12:35-12:50 Marc Funk, COO & President, Lonza Pharma & Biotech: “Novel Tools to Accelerate Early Drug R&D”
12:50-13:05 Daphna Laifenfeld, PhD, Chief Strategy Officer, Ibex Medical Analytics: “Data Driven Repurposing of Existing Drugs”
13:05-13:50 Panel Discussion
Panelists: All
13:50-15:20 Lunch Break
15:20-15:35 Dan Vesely, Co-founder, CliniCrowd, Partner at Sdemagroup: “Patient-driven R&D and the Power of Crowd Source for Therapeutics”
15:35-15:50 Avital Pushett, Business Development, NeuroSense: “Repurposed and Abbreviated ALS Disease Modifying Therapeutic Development”
15:50-16:05 Yoran Bar, Founder & CEO, BeaconCure: “Accelerating Clinical Submissions via Text Analytics AI”
16:05-16:20 Chen Admati, Head of Intel Pharma Analytics Platform, Intel Corporation “From Sensors to Therapeutics via Machine Leaning”
16:20-16:35 Nadav Kidron, CEO, OraMed Pharmaceuticals: “Abbreviated Drug Development: Patient-centered Approaches to Innovation”
16:35-16:50 Natalie Gavrielov, PhD, Scientific Lead, Data2Life: “Patient Voice in R&D – Proactive Drug Safety Monitoring”
16:50-17:05 David Harel, CytoReason: “Data-driven Approach to Discover and Develop Immunotherapy Solutions”
17:05-17:20 Ellen Leinfuss, SVP and Chief Commercial Officer, Certara: “Modeling and Simulations Lead Efficient and Effective Drug Development”
17:20-17:35 Nadav Navon, Chief Operating Officer, Intec Pharma: “The Accordion Pill a Unique Oral Delivery Platform to Enhance Pharmacokinetics and Therapeutic Benefit of Challenging Drugs”
17:35-17:45 Iris Grossman, PhD Chief Scientific Officer, Camp4 Therapeutics: “Closing Remarks”
